To economize SMBG, in 2009, the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended limiting BGTS use to insulin-dependent and gestational diabetes while withdrawing it from most patients with T2D on non-insulin diabetes therapy or no therapy [12]. Here, INS is linked to type 2 diabetes mellitus.